Lv1
28 积分 2022-06-28 加入
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial
13小时前
待确认
Head-to-Head Comparison of mpMRI, PSMA, GRPR PET/CT, and PET/CT Plus MRI for Local Staging of Primary Prostate Cancer and Their Prognostic Value
3天前
已完结
The real‐world outcomes of Lutetium‐177 PSMA‐617 radioligand therapy in metastatic castration‐resistant prostate cancer: Turkish Oncology Group multicenter study
4天前
已完结
Health-related quality of life, pain, and symptomatic skeletal events with [177Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial
4天前
已完结
Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial
4天前
已完结
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
4天前
已完结
Epidemiology and genomics of prostate cancer in Asian men
4天前
已完结
Pediatric-Onset Chronic Inflammatory Demyelinating Polyneuropathy: A Multicenter Study
12天前
已完结
Limited early IVIG for the treatment of pediatric myelin oligodendrocyte glycoprotein antibody-associated disease
23天前
已完结
Prolonged Fever as a Predictor of Coronary Artery Aneurysms Among Children With Kawasaki Disease in North India
23天前
已完结
皖公网安备34019202002308
